Does Microdosing Psilocybin Work for Depression?
Microdosing psilocybin is popular, but the evidence is weaker than most people realize. Here's an honest look at what the research actually shows.
May 18, 2026 · Jordan Mercer
Contents
The best placebo-controlled study on microdosing found no meaningful difference between real doses and placebo. What predicted whether someone felt better was what they believed they had taken.
That is a hard finding for a practice thousands of people say changed their lives, and it is not the same as proof that microdosing does nothing. But if you are looking at it as treatment for depression, you should know that the evidence behind it is thin, and that the strong evidence you have probably read about belongs to something else.
What counts as a microdose
Sub-perceptual. Small enough that nothing looks different, nothing feels strange, and you can hold a normal conversation at work. For dried Psilocybe cubensis that usually means 0.1 to 0.3 g, roughly 1 to 3 mg of psilocybin.
If you are noticing visuals or drift in your thinking, you took a low dose, not a microdose. The threshold is the entire idea.
The schedules people follow:
- Fadiman: one day on, two days off, repeat.
- Stamets: four days on, three days off.
- As needed: dosed before a specific situation, no fixed pattern.
Off-days are there because tolerance to psilocybin builds fast. Dose daily and the effect flattens within a few days. There is nothing special about the number three; the gap just has to be long enough for tolerance to reset.
The study that matters
Nearly everything positive written about microdosing traces back to surveys of people who already microdose. Those results are consistently glowing and consistently unreliable, because the people who tried it, hated it, and quit are not the ones filling out the follow-up questionnaire.
The exception is Szigeti and colleagues, whose 2021 self-blinded citizen science trial in eLife was the largest placebo-controlled psychedelics study published to that point, with 191 people completing the protocol. Participants sourced their own mushrooms and set up their own placebo control by following online instructions, so that neither they nor the researchers knew which capsules held what.
Both groups improved. Microdose and placebo alike reported better wellbeing and psychological function than at baseline, and on most outcomes there was no significant difference between them. The decisive result came from the guesses: when participants were asked which condition they thought they had been in, their belief predicted their outcome far better than the capsules they had actually swallowed.
The caveats are real. The mushrooms were never lab verified, potency was unknown, and self-blinding is imperfect. This is the best naturalistic test anyone has run, not a pharmaceutical-grade double-blind trial. So the honest reading is narrower than “microdosing doesn’t work.” In this design, the drug effect could not be separated from the effect of expecting one.
The mechanism people propose, sub-threshold 5-HT2A activation shifting default mode network activity, or low doses driving neuroplasticity through BDNF, is plausible and unconfirmed in humans at 1 to 3 mg. Hypothesis, not finding.
Full-dose therapy is a different thing
The trials you have heard about are good ones. A 2021 Johns Hopkins randomized trial led by Davis found that two supervised psilocybin sessions with psychological support produced significantly lower depression scores than delayed treatment, with 71% of participants clinically improved within a week. Carhart-Harris and colleagues, the same year, ran psilocybin head to head against escitalopram in a phase 2 trial; the primary outcome showed no statistically significant separation, but secondary measures favored psilocybin, including remission in 57% versus 28%.
Neither study says anything about microdosing. Both used 20 to 30 mg in a supervised room with a therapist present, and the subjective experience is thought to be part of how the treatment works. That has close to nothing in common with 2 mg alone at your kitchen table on a Tuesday morning.
When someone cites “the psilocybin research” to justify a microdosing protocol, this is the substitution being made.
If you’re doing it anyway
Start at 0.1 g. You can go up next time. You cannot come back down once it is in you.
Weigh it, do not eyeball it. The whole premise is staying under the perceptual threshold, and 0.1 g and 0.3 g of ground mushroom look identical. A milligram scale with calibration weights is the basic tool, and DanceSafe sells one; they are a nonprofit that also runs free drug checking at events. Grind a batch to an even powder first, because one cap is not representative of the bag.
Species and batch change the math. P. cubensis runs roughly 0.5 to 1% psilocybin by dry weight. P. azurescens and P. semilanceata can be two to three times stronger per gram, so the same 0.2 g is a different dose entirely. Potency also drifts between flushes of the same species.
Capsules make a weighed dose repeatable. Once ground and weighed, gelatin capsules or vegetarian capsules let you prepare a run in one sitting, and a capsule filling tray helps if you are making a month at a time. They do not improve accuracy on their own. Weigh every dose; never fill by volume.
Do one day before committing to a month. See what 0.1 g does to you before you build a six-week schedule around it.
And do not treat it as a substitute for therapy or medication. Even the people who advocate for microdosing don’t claim that.
Who should not, at any dose
Anyone with a personal or family history of psychosis, schizophrenia, or bipolar I. Psilocybin can trigger psychotic episodes in people predisposed to them, and a small dose is not a safe workaround for that risk.
Lithium. Do not combine with psilocybin at any dose. There are case reports of seizures and cardiac events, and the risk does not appear limited to full doses.
MAOIs. These potentiate psychedelics substantially, which can turn an intended microdose into something much stronger.
SSRIs and SNRIs are less dangerous but likely to blunt the effect, microdoses included. Our drug interactions guide covers the detail.
One more practical matter: psilocybin is Schedule I federally in the US, so possession and distribution are federal crimes. Oregon and Colorado have built regulated therapeutic access, and a number of cities have decriminalized personal possession. Know where your own state sits before you order spores or anything else.
If you are treating a mental health condition, microdosing is not the intervention with evidence behind it. Knowing that in advance is worth more than any protocol.
For the wider picture, see our psilocybin harm reduction guide, and for full experiences the safe psilocybin trip guide. The LSD guide covers a substance with a parallel research story.